Eikon Therapeutics is a new biopharmaceutical company employing single molecule imaging at the interface of chemistry, engineering and biology to discover novel treatments for life-threatening diseases.

Eikon’s live cell imaging drug discovery platform is built on groundbreaking innovations from its founders who pioneered the field of in vivo single-molecule microscopy, and whose work was awarded the Nobel Prize in Chemistry in 2014.

• Industry

  • 3D Imaging
  • Biotechnology

• Milestones

  • Lux investment: 2019

• Founders

  • Eric Betzig
  • Robert Tijan
  • Luke Lavis
  • Xavier Darzacq

  LUX Partners

  • Adam Goulburn

• Latest Tweets